Kenneth C. Anderson, MD, is the Kraft Family Professor of Medicine at Harvard Medical School and director of the LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, MA. 

Over the last 4 decades, he has developed laboratory and animal models of multiple myeloma in its microenvironment, and this has allowed for both the identification of novel targets and the validation of novel targeted therapies. He has rapidly translated these studies to clinical trials, culminating in the US Food and Drug Administration approvals of novel targeted therapies, which have markedly improved patient outcomes. 

Dr Anderson has received the William Dameshek Prize from the American Society of Hematology, the AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research, the David A. Karnofsky Memorial Award and Lecture from the American Society of Clinical Oncology, and the Warren Alpert Foundation Prize from Harvard Medical School. He is a member of the National Academy of Medicine and past president of the International Myeloma Society and the American Society of Hematology. 

Sagar Lonial, MD, FACP, is professor and chair, Department of Hematology and Medical Oncology, and chief medical officer, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. He completed his medical degree at the University of Louisville School of Medicine in Kentucky. He completed his internship and residency at Baylor College of Medicine in Houston, TX, served as chief medical resident at the Ben Taub General Hospital and the Texas Heart Institute at St. Luke’s Hospital, and completed a fellowship in hematology/oncology at Emory University School of Medicine.

Board certified in hematology and medical oncology, Dr Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. Dr Lonial’s research focuses on combination therapy in B-cell malignancies focusing on multiple myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and multiple myeloma. His clinical interests include evaluating the combination of new molecular-targeted agents for B-cell cancers and methods to enhance immunity following allogeneic or autologous stem cell transplantation.

Dr Lonial’s recent research has focused on combinations of novel agents as therapy for multiple myeloma and lymphoma, and, particularly, on evaluating combinations that may result in the synergistic inhibition of the PI3K/AKT pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and the Leukemia & Lymphoma Society. Dr Lonial has authored more than 200 peer-reviewed publications and abstracts. He serves on the editorial boards of the American Journal of Clinical Oncology, the Journal of Clinical Oncology, and Leukemia; is the myeloma editor for Clinical Lymphoma, Myeloma, & Leukemia; and is the hematologic malignancies section editor for Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Haematologica, the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia, The New England Journal of Medicine, and others. He has given a number of local, national, and international presentations. 

Dr Lonial is a member of several local committees and committees for the American Society of Hematology. He is involved in numerous professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He is vice-chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the International Myeloma Society Board of Directors and the International Myeloma Foundation Scientific Advisory Board. He is also a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.

S. Vincent Rajkumar, MD, is the Edward W. and Betty Knight Scripps Professor of Medicine at the Mayo Clinic in Rochester, MN. His academic career was profiled by The Lancet  in the November 26, 2011, issue. 

He is co-chair of the International Myeloma Working Group and chair of the Eastern Cooperative Oncology Group Myeloma Committee. He is the editor in chief of Blood Cancer Journal  and serves as the associate editor for Mayo Clinic Proceedings, Leukemia , and European Journal of Hematology . He also serves on the International Myeloma Foundation Board of Directors and is a member of the National Institutes of Health Myeloma Steering Committee. 

Dr Rajkumar has received several awards, including the 2018 Distinguished Mayo Clinic Investigator Award, the 2019 Giants of Cancer Care Award from OncLive, the 2016 Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, and the 2021 Waldenström Lifetime Achievement Award from the International Myeloma Society. He has also received the Relentless for a Cure Award from the Leukemia & Lymphoma Society in 2010, the John Ultmann Lecture and Award in 2011, and the Janet Davison Rowley Patient Impact Research Award from Cures Within Reach in 2015.  

Dr Rajkumar has more than 750 publications, including more than 450 peer-reviewed original research papers and more than 250 reviews and book chapters.